Compare AMPL & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMPL | CRVS |
|---|---|---|
| Founded | 2012 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.3B |
| IPO Year | 2021 | 2016 |
| Metric | AMPL | CRVS |
|---|---|---|
| Price | $15.85 | $9.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 8 |
| Target Price | $14.77 | ★ $33.14 |
| AVG Volume (30 Days) | ★ 1.6M | 1.2M |
| Earning Date | 11-04-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 11.84 | ★ 48.04 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $343,214,000.00 | N/A |
| Revenue This Year | $19.51 | N/A |
| Revenue Next Year | $15.89 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 14.68 | N/A |
| 52 Week Low | $5.51 | $6.39 |
| 52 Week High | $16.18 | $26.95 |
| Indicator | AMPL | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 69.43 | 32.53 |
| Support Level | $6.05 | $6.39 |
| Resistance Level | N/A | $13.73 |
| Average True Range (ATR) | 0.58 | 0.60 |
| MACD | 0.09 | -0.08 |
| Stochastic Oscillator | 91.04 | 21.18 |
Amplitude Inc is a Software company that provides a Digital Analytics Platform that helps companies analyze their customer behavior within digital products. The Company delivers its application over the Internet as a subscription service using a software-as-a-service (SaaS) model and also it offers customer support related to initial implementation setup, ongoing support services, and application training. The company generates revenue through selling subscriptions to the platform. The company derives a majority of its revenue from the United States, and also has its presence in Internationally.
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.